Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.
<h4>Background</h4>Bevacizumab is believed to be as effective and safe as ranibizumab for ophthalmic diseases; however, its magnitude of effectiveness and safety profile remain controversial. Thus, a meta-analysis and systematic review appears necessary.<h4>Methods</h4>PubMed...
Saved in:
Main Authors: | Bin Wu, Haixiang Wu, Xiaoyan Liu, Houwen Lin, Jin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0101253 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.
by: Christine Schmucker, et al.
Published: (2012-01-01) -
Anti-VEGF treatment switch in real-world DME patients: ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study)
by: Yu Qiang Soh, et al.
Published: (2025-08-01) -
Intravitreal Ranibizumab versus Razumab in treatment naïve diabetic macular edema
by: Dhandapani A, et al.
Published: (2025-06-01) -
Blastocyst selection through an interpretable artificial intelligence method versus traditional morphology grading: study protocol for a randomised controlled trial
by: Lei Chen, et al.
Published: (2025-07-01) -
Intravitreal Ranibizumab for Treatment of Posttraumatic Choroidal Neovascularization: a Case Report
by: A. N. Kulikov, et al.
Published: (2021-10-01)